|
J Biol Chem, Vol. 273, Issue 23, 14261-14268, June 5, 1998
Cyclic Nucleotide Regulation of Type-1 Plasminogen
Activator-Inhibitor mRNA Stability in Rat Hepatoma Cells
IDENTIFICATION OF cis-ACTING SEQUENCES*
Joanne H.
Heaton ,
Maribeth
Tillmann-Bogush,
Nancy S.
Leff, and
Thomas D.
Gelehrter
From the Departments of Human Genetics and Internal Medicine,
University of Michigan Medical School,
Ann Arbor, Michigan 48109-0618
 |
ABSTRACT |
Type-1 plasminogen activator-inhibitor (PAI-1) is
a major physiologic inhibitor of plasminogen activation. Incubation of
HTC rat hepatoma cells with the cyclic nucleotide analogue,
8-bromo-cAMP, causes a dramatic increase in tissue-type plasminogen
activator activity secondary to a 90% decrease in PAI-1 mRNA.
Although 8-bromo-cAMP causes a modest decrease in PAI-1 transcription,
regulation is primarily the result of a 3-fold increase in the rate of
PAI-1 mRNA degradation. To determine the cis-acting
sequences required for cyclic nucleotide regulation, we have stably
transfected HTC cells with chimeric genes containing sequences from the
rat PAI-1 cDNA and the mouse -globin gene and examined the
effect of cyclic nucleotides on the decay rate of these transcripts.
The mRNA transcribed from the -globin gene is stable and not
cyclic nucleotide-regulated, whereas the transcript from a construct
containing the -globin coding region and the PAI-1 3'-untranslated
region (UTR) is destabilized in the presence of 8-bromo-cAMP,
suggesting that this response is mediated by sequences in the PAI-1
3'-UTR. Analyses by deletion of sequences from this chimeric construct
indicate that, whereas more than one region of the PAI-1 3'-UTR can
confer cyclic nucleotide responsiveness, the 3'-most 134-nucleotide
sequence alone is sufficient to do so. Insertion of PAI-1 sequences
within the -globin 3'-UTR confirms that the 3'-most 134 nucleotides
of PAI-1 mRNA can confer cyclic nucleotide regulation of stability
on a heterologous transcript, suggesting that this sequence may play a
major role in hormonal regulation of PAI-1 mRNA stability.
 |
INTRODUCTION |
Eukaryotic gene expression is determined not only by the rate of
gene transcription, but also by the rate at which the transcript is
degraded. The steady state concentration of a particular mRNA, as
well as the rate at which a new transcriptionally induced steady state
is attained, is directly related to the message half-life (1, 2).
Numerous recent studies have been aimed at understanding the role of
specific sequences within the mRNA in determining basal transcript
stability and have led to the identification of consensus sequences
that confer stability or instability to a transcript (2, 3). Although
it is known that many stimuli alter mRNA stability, little is known
about either the cis-acting sequences in the RNA or the
cellular factors involved in regulation of message decay.
Plasminogen activators (PAs)1
are serine proteases that are critical for thrombolysis and also play a
key role in other physiological functions involving tissue remodeling.
Plasminogen activator-inhibitors (PAIs) are specific inhibitors of PAs
and are members of the serine protease inhibitor (serpin) family of
proteins. Type-1 PAI (PAI-1) is a 50 kDa glycoprotein found in plasma,
platelets, and a variety of cell types; its expression is regulated by
growth factors, cytokines, and hormones, including agents that alter
cellular cAMP levels (4).
HTC rat hepatoma cells synthesize and secrete tissue-type plasminogen
activator (tPA) and PAI-1 (5). We have previously reported that
incubation with the synthetic glucocorticoid, dexamethasone, decreases
HTC cell tPA activity by increasing PAI-1 mRNA and protein 5-10-fold, an effect that is entirely explained by an increase in
PAI-1 gene transcription (5-7). In contrast, these cells respond to
cyclic nucleotides with a dramatic ( 50-fold) increase in tPA activity
that is primarily the result of a decrease in PAI-1 mRNA and
protein (8). This effect is time- and
concentration-dependent; a 90% decrease in PAI-1 mRNA
occurs after 12 h of incubation with 1 mM 8-bromo-cAMP
plus 1 mM isobutyl-1-methylxanthine (cA) (8, 9). Nuclear
run-on experiments have shown that cA causes about a 60% decrease in
PAI-1 transcription, not sufficient to account for the decrease in
message accumulation. We have determined the half-life of HTC cell
PAI-1 mRNA by following the decrease in message level either after
inhibition of transcription with actinomycin D or after washing out the
transcriptional inducer, dexamethasone. By either method, PAI-1
mRNA displays a half-life of 4.0-4.5 h. Incubation of cells with
cA accelerates PAI-1 mRNA decay, decreasing the half-life to
1.5 h. Thus, cyclic nucleotides regulate PAI-1 gene expression at
both a transcriptional and posttranscriptional level. Interestingly,
although actinomycin D does not alter the basal rate of PAI-1 mRNA
degradation, it prevents the cA-induced acceleration of decay;
incubation with cyclic nucleotides in the presence of actinomycin D
results in a decay rate identical to that seen in the presence of
actinomycin D alone (7).
The aim of this study is to understand the mechanism by which cyclic
nucleotides regulate PAI-1 mRNA decay by determining the sequences
within the PAI-1 transcript that are required for 8-bromo-cAMP
regulation. We report here that the 3'-UTR of PAI-1 mRNA can confer
cyclic nucleotide regulation on the otherwise stable -globin
mRNA. Deletion analysis of the PAI-1 3'-UTR reveals the presence of
at least two cA-responsive regions; one of these is in the 3'-most 134 nt of PAI-1 mRNA. Furthermore, the 3'-most 134-nt sequence by
itself is able to confer cA responsiveness on the heterologous
-globin mRNA, suggesting that this sequence plays a major role
in the hormonal regulation of PAI-1 mRNA stability.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Eagle's minimal essential medium, glutamine,
fetal calf serum, calf serum, G418, restriction endonucleases (REs),
Taq DNA polymerase, T4 ligase, and TRIzol® were
purchased from Life Technologies, Inc. Bovine serum albumin was
purchased from Intergen Co. (Purchase, NY). Cycloheximide, 8-bromo-cAMP, and isobutyl-1-methylxanthine were purchased from Sigma.
T3 and T7 RNA polymerases, RNase inhibitor, RNase A, and RNase T1 were
purchased from Boehringer Mannheim. -32P-labeled UTP
(specific activity 800 Ci/mmol) was obtained from Amersham Pharmacia
Biotech. The vector pSVL was purchased from Amersham Pharmacia Biotech,
and pBluescriptKS( ) and Escherichia coli AG-1
competent bacteria were purchased from Stratagene (La Jolla, CA). Rat
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA (10) was a
kind gift from Dr. Rodrigo Bravo (Bristol-Myers Squibb).
Oligonucleotide primers used in PCR were synthesized by the University
of Michigan Biomedical Research Core Facilities.
Constructs for Transfection Analysis--
The vector pSVL, which
has an SV40 late promoter upstream and an SV40 polyadenylation signal
downstream from the multicloning site (MCS), was used to drive
expression of the DNA constructs used in these studies. Because the
SV40 late promoter does not appear to be regulated by cyclic
nucleotides, this vector allowed us to examine the effects of cA on
message decay independent of transcriptional effects. All DNA vectors
described below were amplified in E. coli AG-1 competent
bacteria by established procedures (11).
Mouse -globin genomic DNA from position 233 to 1669 (numbering
according to Konkel et al.) (12) was amplified by PCR to include an XbaI site 5' to bp 233 and a BglII
site 3' to bp 1669. This product was subcloned into the XbaI
and BamHI sites of the pSVL MCS to give pSVL G (Fig. 1)
(13).
The chimeric construct of rat PAI-1 and mouse -globin diagrammed in
Fig. 1 was prepared as follows. The 1200-bp coding portion of the
m -globin gene was amplified by PCR to include an XbaI recognition sequence 5' to bp 233 and the BglII recognition
sequence 3' to bp 1436. The 1730-bp 3'-UTR of PAI-1 was PCR-amplified
to generate the sequence with the BglII recognition site 5'
to bp 1331 and the XbaI site 3' to bp 3060. (Nucleotides are
numbered from the start site of transcription (14).) These PCR products were digested with the appropriate REs and subcloned into
XbaI-digested pSVL in a one-step ligation to give the
construct called pSVL G/P. The chimeric construct was verified by
restriction analysis and partial DNA sequence analysis. The neomycin
resistance (neo) gene under control of the cytomegalovirus
promoter was subcloned into the EcoRI site of the pSVL G
and pSVL G/P as well as pSVL.
Constructs having deletions in the 3'-UTR of PAI-1 (Fig. 3) were
prepared from pSVL G/P using convenient RE sites; additional sites in
the neo gene precluded preparing the deletions from the vector containing the neo gene. All deletion constructs
diagrammed in Fig. 3 were prepared in a similar manner, using the
indicated RE digestion to excise a portion of the sequence, incubation
with the Klenow fragment of DNA polymerase to create blunt ends,
followed by self-ligation using T4 DNA ligase. Because the pSVL vector carries recognition sites for NcoI, the construct G/P
AU3A was prepared from
pBluescriptKS( )G/P. In addition, because
m -globin has an NcoI recognition site at position 307, BssHII and NcoI digestion of
pBluescriptKS( )G/P creates three fragments. The 4100-bp
and 1500-bp fragments were gel-purified (leaving behind the 250-bp
fragment to be deleted), incubated with the Klenow fragment of DNA
polymerase to make blunt ends, and ligated. The desired deletion and
the orientation of the fragments were verified by RE analysis and
partial DNA sequencing. In each case, the G/P sequence with the desired
deletion was excised from pSVL or from pBluescriptKS( )
using XbaI and subcloned into the XbaI site in
the MCS of pSVLneo and the identity of the new construct was
confirmed by RE analysis and partial DNA sequencing. Constructs are
designated by the regions of the PAI-1 sequence deleted as indicated in
the diagram at the top of Fig. 3.
We also generated constructs in which portions of sequence from the
PAI-1 3'-UTR were inserted into mouse -globin 3'-UTR as illustrated
in Fig. 5. To provide a site for insertion of PAI-1 sequence, a
BglII recognition site was constructed in the 3'-UTR of
-globin as follows. PCR was used to amplify the -globin gene from
bp 233 to bp 1470, including 5' XhoI and 3' BglII
sites, and a portion of the -globin 3'-UTR from bp 1471 to bp 1668, including 5' BglII and 3' XbaI recognition sites.
The products were cloned into the XhoI and XbaI
sites of pSVLneo in a one step ligation to produce pSVL G/G.
Portions of the PAI-1 3'-UTR were amplified by PCR to include
BglII recognition sites on both the 3' and 5' ends. Each PCR
product was inserted into the pSVL G/G construct by ligation at the
BglII site. Presence of a single insert and orientation were
confirmed by PCR and RE analysis.
Constructs for Riboprobes--
A PCR-amplified fragment of
m -globin from bp 1256 to bp 1436 (which includes coding and intronic
sequence) was subcloned into the PstI and BamHI
sites of the pBluescriptKS( ) MCS. When linearized by
digestion with HindIII (site in the
pBluescriptKS( )) and transcribed using T7 RNA polymerase,
this plasmid generates an antisense riboprobe complementary to 119 nt
of the m -globin coding region mRNA (Fig. 1).
The 177-bp XbaI to AccI fragment of rat GAPDH
cDNA (10) was subcloned into the MCS of
pBluescriptKS( ). This plasmid was digested with
BstEII and transcribed using T3 RNA polymerase to generate
an antisense riboprobe that protects an 80-nt fragment of GAPDH
mRNA.
Preparation of Radiolabeled RNA--
Riboprobes were prepared by
published methods (11). Plasmid DNA (approximately 500 ng) linearized
with the appropriate RE was incubated with T7 or T3 RNA polymerase in
transcription buffer (Boehringer Mannheim) containing RNase inhibitor,
ATP, CTP, GTP, and [32P]UTP at 37 °C for 60 min.
RNase-free DNase I was added, and, after 15 min at 37 °C, the
reaction was extracted with phenol/chloroform (1:1) and the RNA was
precipitated in the presence of ammonium acetate and ethanol. The
labeled RNA was purified by electrophoresis through a 6%
polyacrylamide, 8 M urea gel, eluted from the gel, and
ethanol-precipitated.
Cell Culture--
HTC cells were maintained in monolayer
cultures as described previously (5). In preparation for experiments,
cells were plated in 60-mm tissue culture dishes and grown to
confluence. Cultures were washed in sterile phosphate-buffered saline
(PBS) and incubated in serum-free medium containing 0.1% bovine serum albumin with or without 0.1 mM cycloheximide. After 10-16
h, the medium was removed, the monolayers washed twice with PBS to
remove cycloheximide, and fresh medium with or without cA was added. Cells were harvested at the times indicated for each experiment. For
experiments in which the RNA from the transfected genes was to be
analyzed, incubation with cycloheximide provides two major advantages.
First, cycloheximide significantly enhances expression from the SV40
late promoter (5-50-fold), resulting in easier detection of transcript
from the transfected gene (13). Second, cycloheximide can be readily
removed and its effects completely reversed by washing the monolayers
with PBS and adding fresh medium (15, 16), resulting in a dramatic
decrease in SV40 promoter activity. This protocol allowed us to measure
mRNA degradation without using actinomycin D, which not only
inhibits transcription but also blocks the cA effect on PAI-1 mRNA
(7). Cycloheximide is known to alter the decay rates of some
transcripts (2); however, the degradation rate of endogenous PAI-1
mRNA (determined using actinomycin D to block transcription) in
cells from which cycloheximide has been removed after a 12-h incubation
with the inhibitor, is nearly identical to that in cells not treated
with cycloheximide. Furthermore, in cells transiently treated with
cycloheximide, as in untreated cells, endogenous PAI-1 mRNA decay
is accelerated after incubation of the cells with cA.
Transfections--
HTC cells were transfected using the
Ca2PO4 DNA precipitation technique, and stably
transfected cells were selected in media containing 1 mg/ml G418 as
described previously (17). Colonies of stably transfected cells were
pooled to minimize the possible effects of different integration
sites.
Ribonuclease Protection Analysis--
Total cellular RNA was
isolated either by the method of Chomczynski and Sacchi (7, 18) or by
the TRIzol® reagent method as described by Life
Technologies, Inc. Ribonuclease protection analysis was carried out
essentially as described (11). Total cellular RNA (20-40 µg/sample)
was precipitated and resuspended in 30 µl of hybridization buffer (40 mM Pipes, pH 6.4, 400 mM NaCl, 1 mM
EDTA, 80% formamide) containing 1-5 × 105 cpm of
32P-labeled riboprobe. After 5 min at 85 °C, the samples
were placed at 50 °C for 16-20 h. RNase digestion buffer (350 µl
of 10 mM Tris-Cl, pH 7.4, 300 mM NaCl, 5 mM EDTA, 20 µg/ml RNase A, and 100 units/ml RNase T1) was
added to each reaction. After 30 min at 30 °C, SDS (0.5% final
concentration) and proteinase K (125 µg/ml) were added and incubation
continued at 37 °C for 30 min. The samples were then extracted with
phenol/chloroform and ethanol-precipitated. The RNA pellets were washed
with 80% ethanol, allowed to air-dry, and resuspended in an 80%
formamide gel-loading buffer. Samples were subjected to electrophoresis
through 6% polyacrylamide, 8 M urea gels and the gels were
dried under vacuum. The amount of radioactivity in each protected
fragment was determined by PhosphorImager analysis (Molecular Dynamics,
Sunnyvale, CA). For each sample the signal in the specific band of
interest was normalized to the signal in the 80-nt protected fragment
of GAPDH.
 |
RESULTS |
The 3'-UTR of PAI-1 mRNA Confers Cyclic Nucleotide
Responsiveness onto the -Globin Transcript--
To determine the
sequences in the PAI-1 mRNA involved in the cA regulation of
message stability, we stably transfected HTC cells with DNA constructs
carrying portions of the PAI-1 sequence and examined the degradation
rates of the transcribed mRNAs. The pSVL vector was chosen because
the SV40-late promoter, unlike some other viral promoters, does not
appear to be regulated by 8-bromo-cAMP.2 To confirm
that the cA regulation can be faithfully reproduced in a transfection
system, we first prepared a PAI-1 mini-gene using the SstI
recognition site to delete 530 bp of the coding region, and subcloned
it into the vector pSVLneo. The mRNA transcribed from
the PAI mini-gene can be distinguished from the endogenous PAI-1
mRNA in ribonuclease protection analysis using a PAI-1 riboprobe that overlaps the deleted sequence. The half-life of the transcript from the PAI-1 mini-gene is 4.0 h and is decreased to 2.0 h
in cells treated with cA (data not shown). These results are nearly identical to those observed for endogenous PAI-1 mRNA (7) and confirm that the cyclic nucleotide regulation of the transfected mini-gene faithfully reflects the regulation of the endogenous gene.
These results also confirm that under these conditions cA regulation of
message stability can be reproduced in cells that have been transiently
treated with cycloheximide.
To determine which regions of PAI-1 transcript are involved in the cA
regulation, we prepared chimeric genes of rat PAI-1 and mouse
-globin. The -globin transcript is normally very stable, and its
decay is not regulated by cyclic nucleotides. As a first step, we
compared degradation rates of transcripts from the -globin gene and
a chimeric gene containing globin coding region and the full 3'-UTR of
PAI-1 using the constructs illustrated in Fig. 1. As shown in Fig.
2, transcripts from the stably
transfected pSVL G or pSVL G/P gene can be readily detected in
ribonuclease protection analysis using the 5'G riboprobe. Because there
is no endogenous globin, only the protected 119-nt fragment
representing the -globin coding region and the 80-nt fragment from
the GAPDH control are seen. The 119-nt fragment is not present in the
RNA from non-transfected cells (data not shown).

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 1.
Schematic representation of DNA
constructs. Mouse -globin genomic DNA from bp 233 to bp 1669 was amplified by PCR, and the 1430-bp product was subcloned into the
pSVL MCS to give pSVL G. The m -globin coding sequence (1200 bp
including intronic sequences, solid bar) and the PAI-1
3'-UTR (1730 bp, open bar) were amplified by PCR to include
the restriction endonuclease sites shown. The PCR products were ligated
into the pSVL plasmid as indicated to give pSVL G/P. A template for a
m -globin riboprobe that will recognize 119 bp of the coding region
(5'G riboprobe) was prepared by subcloning a PCR-amplified fragment
from bp 1256 to bp 1436 into the MCS of pBluescriptKS( ).
, poly(A) signal.
|
|

View larger version (49K):
[in this window]
[in a new window]
|
Fig. 2.
Effect of cA on decay rates of transcripts
from chimeric constructs. Following a 10-h incubation in
serum-free medium containing 0.1 mM cycloheximide,
duplicate monolayer cultures of HTC cells stably transfected with pSVL
G (A) or pSVL G/P (B) were washed in PBS and
incubated in serum-free medium with or without 1 mM
8-bromo-cAMP and 1 mM isobutyl-1-methylxanthine. At the
times indicated, the cells were harvested, total RNA isolated, and
ribonuclease protection analysis carried out on 20 µg (pSVL G) or
40 µg (pSVL G/P) RNA per sample using 32P-labeled
riboprobes for 5' globin and for GAPDH (GAP). The sizes of
the protected fragments are: globin, 119 nt; GAPDH, 80 nt. Size markers
in lane M are DNA from HpaII-digested and
32P-labeled pBR322. Duplicate lanes represent duplicate
cultures. C and D, the experiments shown in
panels A and B were analyzed using the
PhosphorImager. For each sample the signal in the globin protected
fragment was normalized to that in the GAPDH fragment, and the data are
presented as a percentage of the amount at time zero. , control;
, cA.
|
|
Quantitative analysis of this experiment is shown in Fig. 2
(C and D). As expected, the -globin transcript
has a long half-life that is not regulated by cA. In this experiment,
the half-life of the transcript from the G/P construct is 8.5 h.
Although not as short as PAI-1, this half-life is much shorter than
that of -globin and is decreased to 3.5 h when cells are
incubated with cA, a 2.4-fold cA-induced increase in decay rate. This
is nearly identical to the cA effect on the PAI-1 mini-gene mRNA.
These results confirm that cA regulation can be reproduced in the
transfection system and demonstrate that the 3'-UTR of PAI-1 mRNA
can confer this regulation onto the -globin transcript. Determinants
of mRNA stability have been described in the coding regions of some transcripts (19-21). However, because it is clear from our results that the 3'-UTR of PAI-1 mRNA is sufficient to confer both an increase in degradation rate and cyclic nucleotide responsiveness on a
heterologous message, we focused our studies on this region.
Deletion Analysis of the PAI-1 3'-UTR--
In an effort to locate
the region within the PAI-1 3'-UTR responsible for cyclic nucleotide
responsiveness, we used convenient restriction endonuclease sites to
delete selected portions of the PAI-1 cDNA in the context of the
G/P construct. The 3'-UTR of PAI-1 mRNA has several sequences of
potential interest (14) illustrated in the top portion of Fig.
3. AU-rich elements (AREs) that include
AUUUA motifs flanked with U-rich stretches have been implicated in the
instability of mRNAs of cytokines and oncogenes (3). The PAI-1
3'-UTR has three AUUUA motifs (ATTTA in the cDNA), two in close
proximity at nt 2053 and 2117, and a third farther downstream at
position 2728, close to the two 70-nt U-rich stretches (T-rich in the
cDNA) (nt 2821-3023). PAI-1 has a highly conserved region in its
3'-UTR; the 127-nt sequence in rat PAI-1 from nt 2506 to nt 2632 is
80% identical in mink, murine, bovine, porcine, and human PAI-1 and
shares 85-97% identity when compared pairwise with each of these
species (14, 22-26). Finally, PAI-1 has an unusual stretch of 39 GpA
dinucleotides between nt 2363 and 2442. The location of these regions
within the 3'-UTR, the RE sites that flank them and the designations
given them are shown in the top of Fig. 3. Regions "A" and "C"
are so named for lack of putative regulatory sequences.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 3.
Schematic representation of deletion
constructs and effect of 8-bromo-cAMP on mRNA half-lives. The
chimeric gene pSVL G/P described in Fig. 1 was the parent plasmid used
to prepare constructs with deletions in the PAI-1 3'-UTR. The positions
of several unique restriction sites and of certain potentially
interesting sequences in the 3'-UTR of PAI-1 are shown at the
top of the figure. The closed triangles ( )
indicate the location of ATTTA pentamers, and the closed bar
( ) represents the 127-bp region that is 80% identical in murine,
rat, bovine, mink, porcine, and human PAI-1. GpA and
TTTs show the locations of the 39 GpA-repeat and the T-rich
regions, respectively. The G/P deletion constructs shown on the
lower left side of the figure were prepared using the RE
sites as described under "Experimental Procedures" and are
designated by the PAI-1 sequence deleted as indicated below the
schematic in the top portion of the figure. HTC cells stably
transfected with each of the deletion constructs were examined for the
effect of cA on the degradation rates of the transcripts as described
in the legend to Fig. 2. The mRNA half-lives calculated from
several experiments are summarized. The means ± S.E. (for the
Globin and G/P constructs, n = 8) or ± S.D. (for
the deletion constructs, n = 2 or 3) are shown. The
ratio of the message half-life in untreated and cA-treated cells was
calculated separately for each experiment and the mean of these ratios
is reported in column Control/cA. , poly(A) signal.
|
|
Deletion constructs of pSVL G/P were made by restriction enzyme
digestion and blunt end ligation as described under "Experimental Procedures" and shown in Fig. 3. HTC cells were stably transfected with each deletion construct, incubated with or without cA, and analyzed by ribonuclease protection analysis using the -globin riboprobe as described above. Fig. 3 summarizes the results from experiments with all of the deletion constructs tested, and Fig. 4 shows examples of data from
representative individual experiments with three of these deletion
constructs. The full-length -globin message decays slowly and shows
no cA regulation, whereas the transcript from the G/P construct, which
has the PAI-1 3'-UTR, is more labile and its degradation is accelerated
in cA-treated cells. Interestingly, all of the deletion constructs
tested exhibit some degree of cyclic nucleotide regulation, suggesting
that two, or possibly more, regions in the 3'-UTR can confer cA
regulation. Of particular interest is the construct G/P 1600 ( 1331-2926) (Figs. 3 and 4B) that retains only the
3'-most 134 nt of the PAI-1 3'-UTR. The half-life of this transcript
was decreased 2.3-fold in cyclic nucleotide-treated cells,
demonstrating that the 3'-most 134-nt sequence of PAI-1 is sufficient
to confer cA responsiveness. However, the construct G/P U II
( 2923-3060), in which only this sequence is deleted, also displays
a 2-fold increase in the rate of degradation in the presence of cA,
consistent with the presence of another upstream regulatory region
(Figs. 3 and 4A). Examination of the other deletion
constructs, such as the G/P U I ( 2718-2926) (Fig.
4C), failed to locate the upstream element because they all
contain the 3'-most 134-nt element, which by itself is sufficient to
mediate cyclic nucleotide responsiveness. The deletion construct G/P
U I + U II also retains cA regulation, suggesting that the other
functional element is located upstream from bp 2714.

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 4.
Effect of 8-bromo-cAMP on decay rates of
transcripts from deletion constructs. HTC cells transfected with
pSVL G/P U II (nt 2923-3060, panel A), pSVL G/P 1600 (nt 1331-2926, panel B), or pSVL G/P U I (nt 2718-2926,
panel C) were analyzed for cyclic nucleotide regulation of
mRNA degradation as described in the legend to Fig. 2. Ribonuclease
protection analysis was carried out on 40 µg of RNA per sample. In
each graph duplicate cultures from a single experiment are shown. ,
control; , cA.
|
|
Insertion Analysis: The 3'-most 134 nt of PAI-1 Is Sufficient to
Confer Cyclic Nucleotide Regulation--
To more clearly define the
cis-acting regions involved in the cA regulation, we
prepared constructs in which selected portions of the PAI-1 3'-UTR
sequence were inserted into the 3'-UTR of the -globin gene (Fig.
5). These constructs were then stably transfected into HTC cells and experiments performed as described above
for the deletion constructs. Results from experiments with four of
these constructs are shown in Fig. 6. The
mRNA transcribed from pSVL G/G, like the -globin transcript, is
stable and not regulated by cyclic nucleotides (Fig. 6A).
However, when the 3'-most 130 nt of PAI-1 sequence (lacking the final 6 A nucleotides; see Fig. 8) was inserted into the globin 3'-UTR (pSVL
G/G + U II), the resultant construct was regulated by cA. Fig.
6B shows a composite of three such experiments; the mean
half-life of 9 h was decreased to 4 h upon incubation with
cA, a 2.2-fold change. The construct pSVL G/G + 1400 nt has an
insertion of 1378 nt of the 5' end of the PAI-1 3'-UTR. The transcript
from this construct displayed a half-life of 4.7 h, which was
decreased to 2.4 h upon incubation with cA (Fig. 6D).
In contrast, the message transcribed from pSVL G/G+U I, which has the
upstream U-rich region, is not cA-regulated (Fig. 6C). These
results confirm that the 3'-most 134-nt region of PAI-1 3'-UTR is
sufficient to confer cyclic nucleotide regulation and that there is at
least one other regulatory element in the upstream region of the
3'-UTR. The PAI-1 sequence between bp 2770 and bp 2923, containing the
upstream U-rich stretch (U I), does not appear to confer cyclic
nucleotide regulation.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 5.
Schematic representation of PAI-1 insertion
constructs. The m -globin sequence from bp 233 to bp 1470 was
prepared by PCR to include a 5' XhoI recognition site and a
BglII site 3' to bp 1470 (solid bar). The
m -globin 3'-UTR from bp 1471 to bp 1669 that includes the
polyadenylation signal ( ) and a 5' BglII site and a 3'
XbaI site was amplified by PCR (hatched bar). The
products were cloned into the XhoI and XbaI sites
of pSVLneo to give the construct pSVL G/G that has a
BglII recognition site 25 bp downstream from the translation
stop codon. PAI-1 fragments of interest were prepared by PCR to include
BglII recognition sites on both the 5' and 3' ends and were
ligated into the BglII site of pSVL G/G. The resultant
constructs are designated by the region of the PAI-1 sequence
inserted.
|
|

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 6.
Effect of 8-bromo-cAMP on decay rates of
transcripts from insertion constructs. Experiments were carried
out as described in the legend to Fig. 2 using HTC cells transfected
with pSVL G/G (panel A), pSVL G/G + UII (bp 2925-3054,
panel B), pSVL G/G + U I (bp 2714-2926, panel C)
or pSVL G/G + 1400 nt (1331-2709, panel D). Ribonuclease
protection analysis was carried out on 40 µg of RNA per sample. In
panel A the average ± S.E. of five experiments (10 cultures) and in panel B the average ± S.E. of three
experiments (6 cultures) are shown. In panels C and
D, duplicate cultures from a single experiment are shown.
, control; or , cA.
|
|
Because the functional cyclic nucleotide-responsive element includes
one of the two U-rich regions, we attempted to determine whether this
sequence alone was sufficient. Fig. 7
shows the results of experiments carried out with HTC cells stably
transfected with constructs that have inserts of either one or both of
the U-rich regions, as well as two other upstream portions of the PAI-1
3'-UTR. These results show that neither of the U-rich regions alone (bp 2770-2923 or bp 2925-3024) nor both together (bp 2710-3024), can confer cA responsiveness, and suggest that the final, A-rich, 30 nt of
the 3'-most 134-nt sequence is required. Fig.
8 shows the 134-nt cA-responsive sequence
with the U-rich and A-rich regions highlighted.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 7.
Effect of 8-bromo-cAMP on decay rates of
transcripts from insertion constructs. PAI-1 insertion constructs
were prepared as described in Fig. 5. The left side of the
figure shows the PAI-1 sequence numbers and regions of potential
interest (as defined in the legend to Fig. 3) included in each
insertion. The ability of the insert to confer cA-induced
destabilization of the transcript is shown on the right,
where a "+" indicates a control/cA ratio of mRNA half-lives
greater than 2.2 and a " " indicates a ratio of less than
1.4.
|
|

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 8.
Sequence of the 3'-most 134 nt of the rat
PAI-1 3'-UTR. The sequence to PAI-1 mRNA from nt 2927 to nt
3060 as reported by Zeheb et al. (14) is shown. The U-rich
region is underlined, and the A-rich region is designated by
a bold underline.
|
|
 |
DISCUSSION |
In this study, we have examined the mechanism by which cyclic
nucleotides accelerate the rate of rat HTC cell PAI-1 mRNA
degradation. We have shown that sequences in the 3'-UTR of PAI-1 can
confer both instability and cA regulation of degradation on the
otherwise stable and non-regulated mouse -globin mRNA. The PAI-1
3'-UTR has at least two cA-responsive elements; one of these elements is in the 3'-most 134 nt, which by itself is able to confer cA regulation on the globin message.
Studies from several laboratories have defined specific elements in the
3'-UTR of transcripts that are responsible for their relative
stability. With a few exceptions (2, 27), these have all been
instability determinants. The most extensively studied instability
determinants are the AU-rich elements, or AREs, found in the 3'-UTR of
many highly labile transcripts including those of proto-oncogenes (28,
29), growth factors (30), and cytokines (31, 32). AREs may have either
multiple AUUUA motifs resulting in the nonomer UUAUUUA(U/A)(U/A) (28),
AUUUA motifs scattered in a generally U-rich sequence, or an AU-rich
region without an AUUUA motif (3). In addition, two U-rich domains in
the yeast MFA2 3'-UTR appear to be involved in regulation of
poly(A) nuclease activity (33) and a 29-nt U-rich sequence in human
amyloid precursor protein mRNA has been implicated in regulation of
its degradation (34).
Rat PAI-1 has two AUUUAs in close proximity at nt positions 2053 and
2117, but these are not in an otherwise AU-rich region. A third AUUUA
sequence is near the two 70-nt U-rich stretches (nt 2821-2892 is 57%
U and nt 2952-3023 is 51% U, separated by a 60-nt sequence that is
only 20% U), making this region a candidate as an instability
determinant. Interestingly, one of these U-rich regions is included in
the 3'-most 134-nt fragment that is able to confer both an increase in
basal degradation rate and cA regulation of decay on the -globin
transcript. Although the U-rich region may be involved in the cyclic
nucleotide responsiveness, it is not by itself sufficient as seen by
the results shown in Fig. 7. Decay rates of transcripts from G/G
constructs carrying either one or both of the U-rich sequences, but
lacking the last 30 nt, are not regulated by cA. In addition, the
upstream functional element(s), is not simply the upstream U-rich
sequence, as evidenced by the fact that constructs lacking both U I and
U II (G/P U I + U II (Fig. 3) and G/G + 1400 nt (Figs. 6 and 7))
display cA regulation of mRNA decay.
The growing number of reports of hormone, growth factor, and cytokine
regulation of mRNA stability reflects the growing realization of
the importance of this process in overall regulation of gene expression. Rapid changes in the abundance of a short-lived transcript can be effected by a small change in the half-life (2). There are now
several studies that have identified cis-acting sequences and/or trans-acting factors potentially involved in hormonal
regulation of degradation. The dramatic stabilization of the frog liver
vitellogenin mRNA is mediated by binding of an estrogen-inducible
protein, recently identified as the KH domain protein, vigilin, to a
27-nt sequence within the 3'-UTR (35, 36). Tumor necrosis factor- induces a 4-fold stabilization of GLUT1 mRNA in 3T3-L1
pre-adipocytes, which appears to be mediated by a 105-nt GC-rich
portion of the 3'-UTR and is correlated with increased protein binding
to the 3'-UTR (37). Stabilization of amyloid precursor protein mRNA in activated peripheral blood mononuclear cells is accompanied by an
increase in binding of a protein to a 29-nt U-rich element in the
3'-UTR (38). Finally, in rat pituitary cultures, thyroid hormone
accelerates degradation of thyrotropin message and causes an
increased binding of a cellular factor to a 41-nt portion of the 3'-UTR
of the transcript (39). This 41 nt includes a 12-nt consensus sequence
found in several unstable mRNAs, including the 3'-most 134 nt of
PAI-1 mRNA (11 of the 12-nt consensus at nt 3010-3020).
Agents that elevate cellular cAMP levels also have been shown to
regulate mRNA degradation, in some cases stabilizing message (40-42), but more often causing down-regulation of mRNAs.
Treatment of rat Sertoli cells with follicle-stimulating hormone causes destabilization of androgen receptor, follicle-stimulating hormone receptor, and G-protein -subunit mRNAs (43-45). In both rat
ovary and human endometrial stromal cells, luteinizing hormone/human chorionic gonadotropin receptor mRNA is down-regulated by human chorionic gonadotropin, apparently through accelerated degradation (46,
47). Cyclic nucleotide analogues also destabilize asialoglycoprotein receptor mRNA in HepG2 cells (48), tyrosine aminotransferase in H4
rat hepatoma cells (49), angiotensin type I and type II receptor
mRNA (50, 51) and the kidney-specific transcription factor, LFB3,
mRNA in porcine kidney cells in culture (52). In two cases, cA
regulation of message stability has been associated with binding of
proteins to the 3'-UTR of the transcript. Chlorophenylthio-cAMP both
stabilizes rat hepatoma cell phosphoenolpyruvate carboxykinase mRNA
10-fold and decreases the binding of a 100-kDa protein to the 3'-UTR of
this transcript (53). In hamster smooth muscle cells, isoproterenol
destabilizes 2-adrenergic receptor mRNA and
increases the binding of both an AUF1 related protein and a more
specific ARB protein to the 3'-UTR of 2-adrenergic
receptor mRNA (54, 55). Sequences in human and hamster
2-adrenergic receptor mRNAs that are A+U-rich have
been implicated in both protein binding and regulation of message
stability (56, 57). The 134-nt region that we find to confer cA
regulation of PAI-1 mRNA stability has both a U-rich and an A-rich
region (Fig. 8), similar but not identical to those in
2-adrenergic receptor mRNA.
The cyclic nucleotide regulation of PAI-1 mRNA accumulation, first
observed in HTC cells (8), has also been demonstrated in rat testicular
peritubular cells (58), astrocytes (59) and osteoblasts (60), mink lung
epithelial cells (61), human fibrosarcoma cells (62), umbilical vein
endothelial cells (63), and synovial cells (64). Our previous
experiments have shown that in rat HTC cells, whereas transcriptional
regulation plays a role in the cA-induced decrease in PAI-1, the major
effect is on message stability. The studies reported here demonstrate
that at least two elements in the 3'-UTR of PAI-1 mRNA are involved in regulation of PAI-1 message decay. One of these regulatory elements
is the 3'-most 134 nt. We have found that a number of cellular proteins
interact with the same PAI-1 sequence that can confer cA
regulation,3 suggesting that
one or more of these factors may play a role in cyclic nucleotide
regulation. Our current studies are aimed at delineating the exact
sequences responsible for the cyclic nucleotide regulation of mRNA
degradation and defining the binding proteins involved in this
regulation, as well as identifying the other cis-acting
element(s) in the PAI-1 3'-UTR.
 |
ACKNOWLEDGEMENT |
We thank Erin Janssen for technical assistance
during her tenure on a Summer Student Research Program Fellowship from
the Michigan Diabetes Research and Training Center.
 |
FOOTNOTES |
*
This work was supported by Public Health Service Grant
CA22729 from the National Cancer Institute (to T. D. G.) and
National Research Service Award DK09437 from the National Institutes of Health (to M. T.-B.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Human
Genetics, M4708 MSII/0618, University of Michigan Medical School, 1301 E. Catherine St., Ann Arbor, MI 48109-0618. Tel.: 734-763-3460 or
734-764-5491; Fax: 734-763-5831; E-mail: heatonj{at}umich.edu.
1
The abbreviations used are: PA, plasminogen
activator; PAI, plasminogen activator-inhibitor; PAI-1, type-1 PAI;
UTR, untranslated region; tPA, tissue-type plasminogen activator; PCR,
polymerase chain reaction; nt, nucleotide(s); bp, base pair(s); Pipes,
1,4-piperazinediethanesulfonic acid; GAPDH, glyceraldehyde-3-phosphate
dehydrogenase; PBS, phosphate-buffered saline; MCS, multicloning site;
cA, 8-bromo-cAMP plus isobutyl-1-methylxanthine; ARE, AU-rich element;
RE, restriction endonuclease.
2
J. H. Heaton and T. D. Gelehrter,
unpublished observation.
3
M. Tillmann-Bogush, J. H. Heaton, and T. D. Gelehrter, manuscript in preparation.
 |
REFERENCES |
-
Hargrove, J. L.,
Hulsey, M. G.,
and Beale, E. G.
(1991)
BioEssays
13,
667-674[CrossRef][Medline]
[Order article via Infotrieve]
-
Ross, J.
(1995)
Microbiol. Rev.
59,
423-450[Abstract/Free Full Text]
-
Chen, C.-Y.,
and Shyu, A.-B.
(1995)
Trends Biochem. Sci.
20,
465-470[CrossRef][Medline]
[Order article via Infotrieve]
-
Andreasen, P. A,
Georg, B.,
Lund, L. R.,
Riccio, A.,
and Stacey, S. N.
(1990)
Mol. Cell. Endocrinol.
68,
1-19[CrossRef][Medline]
[Order article via Infotrieve]
-
Gelehrter, T. D.,
Sznycer-Laszuk, R.,
Zeheb, R.,
and Cwikel, B. J.
(1987)
Mol. Endocrinol.
1,
97-101[Abstract/Free Full Text]
-
Heaton, J. H.,
and Gelehrter, T. D.
(1989)
Mol. Endocrinol.
3,
349-355[Abstract/Free Full Text]
-
Heaton, J. H.,
Kathju, S.,
and Gelehrter, T. D.
(1992)
Mol. Endocrinol.
6,
53-60[Abstract/Free Full Text]
-
Heaton, J. H.,
and Gelehrter, T. D.
(1990)
Mol. Endocrinol.
4,
171-178[Abstract/Free Full Text]
-
Barouski-Miller, P. A.,
and Gelehrter, T. D.
(1982)
Proc. Natl. Acad. Sci. U. S. A.
79,
2319-2322[Abstract/Free Full Text]
-
Fort, Ph,
Marty, L.,
Piechaczyk, M.,
El Sabrouty, S.,
Dani, Ch,
Jeanteur, Ph,
and Blanchard, J. M.
(1985)
Nucleic Acids Res.
13,
1431-1442[Abstract/Free Full Text]
-
Ausubel, F. M.,
Brent, R.,
Kingston, R. E.,
Moore, D. D.,
Seidman, J. G.,
Smith, J. A.,
and Struhl, K.
(1989)
Current Protocols in Molecular Biology, pp. 1.1.1-1.8.9 and 4.7.1-4.7.8, Greene and Wiley Interscience, New York
-
Konkel, D. A.,
Maizel, J. V., Jr.,
and Leder, P.
(1979)
Cell
18,
865-873[CrossRef][Medline]
[Order article via Infotrieve]
-
Kathju, S.
(1994)
Regulation of Tissue Type Plasminogen Activator Gene Expression by Glucocorticoids and Cyclic Nucleotides in Rat Hepatoma Cells.Ph.D. dissertation, University of Michigan, Ann Arbor
-
Zeheb, R.,
and Gelehrter, T. D.
(1988)
Gene (Amst.)
73,
459-468[CrossRef][Medline]
[Order article via Infotrieve]
-
Peterkofsky, B.,
and Tomkins, G. M.
(1968)
Proc. Natl. Acad. Sci. U. S. A.
60,
222-228[Free Full Text]
-
Gelehrter, T. D.,
and Tomkins, G. M.
(1970)
Proc. Natl. Acad. Sci. U. S. A.
66,
390-397[Abstract/Free Full Text]
-
Kathju, S.,
Heaton, J. H.,
Bruzdzinski, C. J.,
and Gelehrter, T. D.
(1994)
Endocrinology
135,
1195-1204[Abstract]
-
Chomczynski, P.,
and Sacchi, N.
(1987)
Anal. Biochem.
162,
156-159[Medline]
[Order article via Infotrieve]
-
Caponigro, G.,
Muhlrad, D.,
and Parker, R.
(1993)
Mol. Cell. Biol.
13,
5141-5148[Abstract/Free Full Text]
-
Schiavi, S. C.,
Wellington, C. L.,
Shyu, A.-B.,
Chen, C.-Y. A.,
Greenberg, M. E.,
and Belasco, J. G.
(1994)
J. Biol. Chem.
269,
3441-3448[Abstract/Free Full Text]
-
Wellington, C. L.,
Greenberg, M. E.,
and Belasco, J. G.
(1993)
Mol. Cell. Biol.
13,
5034-5042[Abstract/Free Full Text]
-
Bijnens, A. P.,
Knockaert, I.,
Cousin, E.,
Kruithof, E. K. O.,
and Declerck, P. J.
(1997)
Thromb. Haemostasis
77,
350-356[Medline]
[Order article via Infotrieve]
-
Chuang, T.-H.,
Hamilton, R. T.,
and Nilsen-Hamilton, M.
(1995)
Gene (Amst.)
162,
303-308[CrossRef][Medline]
[Order article via Infotrieve]
-
Ginsburg, D.,
Zeheb, R.,
Yang, A. Y.,
Rafferty, U. M.,
Andreasen, P. A.,
Nielsen, L.,
Dano, K.,
Lebo, R. V.,
and Gelehrter, T. D.
(1986)
J. Clin. Invest.
78,
1673-1680
-
Mimuro, J.,
Sawdey, M.,
Hattori, M.,
and Luskutoff, D. J.
(1989)
Nucleic Acids Res.
17,
8872[Free Full Text]
-
Prendergast, G. C.,
Diamond, L. E.,
Dahl, D.,
and Cole, M. D.
(1990)
Mol. Cell. Biol.
10,
1265-1269[Abstract/Free Full Text]
-
Weiss, I. M.,
and Liebhaber, S. A.
(1995)
Mol. Cell. Biol.
15,
2457-2465[Abstract]
-
Herrick, D. J.,
and Ross, J.
(1994)
Mol. Cell. Biol.
14,
2119-2128[Abstract/Free Full Text]
-
Zubiaga, A. M.,
Belasco, J. G.,
and Greenberg, M. E.
(1995)
Mol. Cell. Biol.
15,
2219-2230[Abstract]
-
Shaw, G.,
and Kamen, R.
(1986)
Cell
46,
659-667[CrossRef][Medline]
[Order article via Infotrieve]
-
Gorospe, M.,
and Baglioni, C.
(1994)
J. Biol. Chem.
269,
11845-11851[Abstract/Free Full Text]
-
Stoecklin, G.,
Hahn, S.,
and Moroni, C.
(1994)
J. Biol. Chem.
269,
28591-28597[Abstract/Free Full Text]
-
Muhlrad, D.,
and Parker, R.
(1992)
Genes Dev.
6,
2100-2111[Abstract/Free Full Text]
-
Zaidi, S. H. E.,
and Malter, J. S.
(1994)
J. Biol. Chem.
269,
24007-24013[Abstract/Free Full Text]
-
Dodson, R. E.,
and Shapiro, D. J.
(1994)
Mol. Cell. Biol.
14,
3130-3138[Abstract/Free Full Text]
-
Dodson, R. E.,
and Shapiro, D. J.
(1997)
J. Biol. Chem.
272,
12249-12252[Abstract/Free Full Text]
-
McGowan, K. M.,
Police, S.,
Winslow, J. B.,
and Pekala, P. H.
(1997)
J. Biol. Chem.
272,
1331-1337[Abstract/Free Full Text]
-
Zaidi, S. H. E.,
Denman, R.,
and Malter, J. S.
(1994)
J. Biol. Chem.
269,
24000-24006[Abstract/Free Full Text]
-
Leedman, P. J.,
Stein, A. R.,
and Chin, W. W.
(1995)
Mol. Endocrinol.
9,
375-387[Abstract/Free Full Text]
-
Chedrese, P. J.,
Kay, T. W. H.,
and Jameson, J. L.
(1994)
Endocrinology
134,
2475-2481[Abstract/Free Full Text]
-
Chen, M.,
Schnermann, J.,
Smart, A. M.,
Brosius, F. C.,
Killen, P. D.,
and Briggs, J. P.
(1993)
J. Biol. Chem.
268,
24138-24144[Abstract/Free Full Text]
-
Huang, D.,
Hubbard, C. J.,
and Jungmann, R. A.
(1995)
Mol. Endocrinol.
9,
994-1004[Abstract/Free Full Text]
-
Blok, L. J.,
Hoogerbrugge, J. W.,
Themmen, A. P.,
Baarends, W. M.,
Post, M.,
and Grootegoed, J. A.
(1992)
Endocrinology
131,
1343-1349[Abstract/Free Full Text]
-
Themmen, A. P. N.,
Blok, L. J.,
Post, M.,
Baarends, W. M.,
Hoogerbrugge, J. W.,
Parmentier, M.,
Vassart, G.,
and Grootegoed, J. A.
(1991)
Mol. Cell. Endocrinol.
78,
R7-R13[CrossRef][Medline]
[Order article via Infotrieve]
-
Loganzo, F., Jr.,
and Fletcher, P. W.
(1993)
Mol. Endocrinol.
7,
434-440[Abstract/Free Full Text]
-
Lu, D. L.,
and Menon, K. M. J.
(1996)
Biochemistry
35,
12347-12353[CrossRef][Medline]
[Order article via Infotrieve]
-
Han, S. W.,
Lei, Z. M.,
and Rao, C. V.
(1997)
Biol. Reprod.
57,
158-164[Abstract]
-
Stockert, R. J.
(1993)
J. Biol. Chem.
268,
19540-19544[Abstract/Free Full Text]
-
Smith, J. D.,
and Liu, A. Y.-C.
(1988)
EMBO J.
7,
3711-1716[Medline]
[Order article via Infotrieve]
-
Wang, X.,
Nickenig, G.,
and Murphy, T. J.
(1997)
Mol. Pharmacol.
52,
781-787[Abstract/Free Full Text]
-
Murasawa, S.,
Matsubara, H.,
Kijima, K.,
Maruyama, K.,
Ohkubo, N.,
Mori, Y.,
Iwasaka, T.,
and Inada, M.
(1996)
Hypertens. Res.
19,
271-279[Medline]
[Order article via Infotrieve]
-
Marksitzer, R.,
Stief, A.,
Menoud, P.-A.,
and Nagamine, Y.
(1995)
J. Biol. Chem.
270,
21833-21838[Abstract/Free Full Text]
-
Nachaliel, N.,
Jain, D.,
and Hod, Y.
(1993)
J. Biol. Chem.
268,
24203-24209[Abstract/Free Full Text]
-
Hadcock, J. R.,
Wang, H.,
and Malbon, C. C.
(1989)
J. Biol. Chem.
264,
19928-19933[Abstract/Free Full Text]
-
Pende, A.,
Tremmel, K. D.,
DeMaria, C. T.,
Blaxall, B. C.,
Minobe, W. A.,
Sherman, J. A.,
Bisognano, J. D.,
Bristow, M. R.,
Brewer, G.,
and Port, J. D.
(1996)
J. Biol. Chem.
271,
8493-8501[Abstract/Free Full Text]
-
Danner, S.,
Frank, M.,
and Lohse, M. J.
(1998)
J. Biol. Chem.
273,
3223-3229[Abstract/Free Full Text]
-
Tholanikunnel, B. G.,
and Malbon, C. C.
(1997)
J. Biol. Chem.
272,
11471-11478[Abstract/Free Full Text]
-
Nargolwalla, C.,
McCabe, D.,
and Fritz, I. B.
(1990)
Mol. Cell. Endocrinol.
70,
73-80[CrossRef][Medline]
[Order article via Infotrieve]
-
Tranque, P.,
Robbins, R.,
Naftolin, F.,
and Andrade-Gordon, P.
(1992)
Glia
6,
163-171[CrossRef][Medline]
[Order article via Infotrieve]
-
Fukumoto, S.,
Allan, E. H.,
Yee, J. A.,
Gelehrter, T. D.,
and Martin, T. J.
(1992)
J. Cell. Physiol.
152,
345-355
-
Thalacker, F. W.,
and Nilsen-Hamilton, M.
(1992)
Biochem. J.
287,
855-862
-
Georg, B.,
Riccio, A.,
and Andreasen, P.
(1990)
Mol. Cell. Endocrinol.
72,
103-110[CrossRef][Medline]
[Order article via Infotrieve]
-
Konkle, B. A.,
Kollros, P. R.,
and Kelly, M. D.
(1990)
J. Biol. Chem.
265,
21867-21873[Abstract/Free Full Text]
-
DiBattista, J. A.,
Martel-Pelletier, J.,
Morin, N.,
and Jolicoeur, F. C.
(1994)
Mol. Cell. Endocrinol.
103,
139-148[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
F. Angenstein, A. M. Evans, S.-C. Ling, R. E. Settlage, S. Ficarro, F. A. Carrero-Martinez, J. Shabanowitz, D. F. Hunt, and W. T. Greenough
Proteomic Characterization of Messenger Ribonucleoprotein Complexes Bound to Nontranslated or Translated Poly(A) mRNAs in the Rat Cerebral Cortex
J. Biol. Chem.,
February 25, 2005;
280(8):
6496 - 6503.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. H. Smith, S. R. Coats, H. Qin, M. S. Petrie, J. W. Covington, M. Su, M. Eren, and D. E. Vaughan
Differential and Opposing Regulation of PAI-1 Promoter Activity by Estrogen Receptor {alpha} and Estrogen Receptor {beta} in Endothelial Cells
Circ. Res.,
August 6, 2004;
95(3):
269 - 275.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Shetty, K. Bdeir, D. B. Cines, and S. Idell
Induction of Plasminogen Activator Inhibitor-1 by Urokinase in Lung Epithelial Cells
J. Biol. Chem.,
May 9, 2003;
278(20):
18124 - 18131.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Zierold, J. A. Mings, and H. F. DeLuca
Parathyroid hormone regulates 25-hydroxyvitamin D3-24-hydroxylase mRNA by altering its stability
PNAS,
October 31, 2001;
(2001)
241516798.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Takeda, T. Ichiki, T. Tokunou, N. Iino, S. Fujii, A. Kitabatake, H. Shimokawa, and A. Takeshita
Critical Role of Rho-Kinase and MEK/ERK Pathways for Angiotensin II-Induced Plasminogen Activator Inhibitor Type-1 Gene Expression
Arterioscler. Thromb. Vasc. Biol.,
May 1, 2001;
21(5):
868 - 873.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Xu and T. J. Murphy
Reconstitution of Angiotensin Receptor mRNA Down-regulation in Vascular Smooth Muscle. POST-TRANSCRIPTIONAL CONTROL BY PROTEIN KINASE A BUT NOT MITOGENIC SIGNALING DIRECTED BY THE 5'-UNTRANSLATED REGION
J. Biol. Chem.,
March 10, 2000;
275(11):
7604 - 7611.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Seki, A. M. Healy, D. S. Fletcher, T. Noguchi, and T. D. Gelehrter
IL-1beta mediates induction of hepatic type 1 plasminogen activator inhibitor in response to local tissue injury
Am J Physiol Gastrointest Liver Physiol,
October 1, 1999;
277(4):
G801 - G809.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Tillmann-Bogush, J. H. Heaton, and T. D. Gelehrter
Cyclic Nucleotide Regulation of PAI-1 mRNA Stability. IDENTIFICATION OF CYTOSOLIC PROTEINS THAT INTERACT WITH AN A-RICH SEQUENCE
J. Biol. Chem.,
January 8, 1999;
274(2):
1172 - 1179.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. H. Heaton, W. M. Dlakic, M. Dlakic, and T. D. Gelehrter
Identification and cDNA Cloning of a Novel RNA-binding Protein That Interacts with the Cyclic Nucleotide-responsive Sequence in the Type-1 Plasminogen Activator Inhibitor mRNA
J. Biol. Chem.,
January 26, 2001;
276(5):
3341 - 3347.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Zierold, J. A. Mings, and H. F. DeLuca
Parathyroid hormone regulates 25-hydroxyvitamin D3-24-hydroxylase mRNA by altering its stability
PNAS,
November 20, 2001;
98(24):
13572 - 13576.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|